0.419522.09% ( +0.0759 )
Delay Trading: Nov 10, 14:26:56 (EDT)Current ValuationThe current P/E ratio is -0.34, above the reasonable range, cheaper than 3.38% of the time in the past 5 years, and the industry ranks 83/256, the industry Median -1.08.
-0.338xP/E
$0.34Stock price
$-1.02Earnings per share
-0.338xP/E
Stock price$0.34Earnings per share$-1.02
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -1.87x
- Typical range
- -3.44x–-0.90x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
03876114152
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
BAYZFUSBayer Aktiengesellschaft | -37.57x | -- | $62.45B |
BAYRYUSBayer | -37.61x | -- | $62.52B |
VTRSUSViatris | -38.65x | 97.55% | $23.49B |
ELANUSElanco Animal Health | -91.26x | 146.23% | $13.42B |
ABVXUSAbivax SA | -16.31x | 22.99% | $7.58B |
AXSMUSAxsome Therap | -44.80x | 29.75% | $7.05B |
CURLFUSCuraleaf Holdings, Inc. | -333.04x | -- | $6.87B |
VREOFUSVIREO GROWTH INC | -95.96x | -- | $6.44B |
BLTEUSBelite Bio | -62.04x | 29.87% | $6.35B |
MANEUSVeraDermics | -57.67x | 97.44% | $6.01B |
DFTXUSDefinium Therapeutics | -14.09x | 44.54% | $4.76B |
AMLXUSAmylyx Pharmaceuticals | -23.80x | 1.63% | $3.88B |
ELVNUSEnliven Therapeutics | -33.43x | 2.84% | $3.79B |
TARSUSTarsus Pharmaceuticals | -4.97x | 879.07% | $3.49B |
BHCUSBausch Health | -3.74x | 511.90% | $3.14B |
XERSUSXeris Biopharma | -446.06x | -- | $2.90B |
RGCUSRegencell Bioscience | -238.17x | -- | $2.79B |
MBXUSMBX Biosciences | -17.94x | 34.28% | $2.60B |
PHVSUSPharvaris BV | -12.21x | 10.43% | $2.42B |
SEPNUSSepterna | -40.14x | 64.24% | $2.37B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
